Publications

Gould P, Coskey D, Ma X, Wang S, Godbole S, Bond D, Ip A, Ananth S, Varma S, Ayers E, Faden R, Gillespie C, William B, Jacobs R, Hu B, Lattin J, Russler-Germain D, Stanchina M, Rose A, Randall M, Spinner M, Srikakulapu V, Geethakumari PR, Skarbnik A, Chitty DW, Tsang M, Duarte C, Major A, Bock AM, Baron K, Hess B, Tolu S, Pro B, Vaidya S, Amengual JE, Reshef R, Cherng HJ. Post-treatment circulating tumor DNA in large B-cell lymphoma with an immunoglobulin-based assay: real-world outcomes. Haematologica. 2026. PMID: 42610418

Nagpal S, Carlson-Clarke B, Rout SS, Trinh TTH, Roy-O'Reilly M, Tedjakusuma SN, Taiwo R, Harary PM, Granucci M, Chernikova SB, Bertrand S, Therkelsen KE, Han SS, Gu B, Bharani KL, Newman JM, Barisano G, Umeh-Garcia MC, Herrick D, Vogel H, Arora M, Samos CH, Soltys SG, Pollom EL, Rahimy E, Iv M, Melisko ME, Hayden Gephart M. Phase 2 test of QBS72S for breast cancer leptomeningeal disease. Neuro-oncology. 2026. PMID: 42565554

Rugo HS, Ryan JC. P-VERIFY: Real-World Comparative Overall Survival and Progression-Free Survival of CDK4/6 Inhibitors Plus an Aromatase Inhibitor in Patients with HR+/HER2- Metastatic Breast Cancer in the USA-A Vodcast. Targeted oncology. 2026. PMID: 42560565

Bui TBV, Wolf DM, Bruck MC, Moore K, Lien J, Choi SDW, Warhadpande S, Parizadeh A, Dillon D, Overmoyer B, Lynce F, Brown-Swigart L, Hirst GL, Yau C, I-SPY2 Investigators, Nijman IJ, Burgering BMT, Harris IS, Esserman LJ, van 't Veer LJ, Rosenbluth JM. Biomarker-guided responses in patient-derived organoids predict effective therapies in breast cancer. Cell reports. Medicine. 2026. PMID: 42561946

Rasche L, Schinke C, Touzeau C, Minnema MC, van de Donk N, Rodriguez-Otero P, Mateos MV, Ye JC, Tomlinson C, Vishwamitra D, Singh I, Qin X, Campagna M, Masterson T, Vreys V, Lau BW, Tolbert J, Renaud T, Heuck C, Chari A. Talquetamab in patients with relapsed/refractory multiple myeloma: 3-year follow-up of the phase 1/2 MonumenTAL-1 study. Blood. 2026. PMID: 42561120

Rugo HS, Schmid P, Cortes J, Takano T, Fasching PA, Park YH, Bianchini G, Franco SX, Villarreal-Garza C, Tredan O, Yin Y, Barroso-Sousa R, Peng X, Malhotra U, Smith KL, Bardia A. TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS <10. Future oncology (London, England). 2026. PMID: 42535874

Isaacs C, Nanda R, Yau C, Chien AJ, Hershman DL, Stringer-Reasor EM, Wallace AM, Thomas A, Vaklavas C, Clark AS, Kennedy LC, Sanford A, Boughey JC, Albain KS, Pusztai L, Kalinsky KM, Beckwith H, Williams NO, Han HS, Falkson C, Arora M, Elias AD, Pohlmann PR, Rozenblit M, Marshall N, Chen YY, Trivedi MS, McGuinness JE, Howard FM, Chen N, Khoury K, Lancaster RB, Yeung KT, Douglas E, Wei M, Mainor C, LeStage B, Delson AL, Asare AL, Brown-Swigart L, Hirst GL, Matthews JB, Perlmutter J, Symmans WF, Yee D, Hylton NM, van 't Veer LJ, Rugo HS, DeMichele AM, Berry DA, Esserman LJ. Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial. JAMA oncology. 2026. PMID: 42530945

Pecoraro G, De Giorgi A, Montelatici G, Salfi G, Lin HM, Turco F, Taha T, Beltran H, de Bono J, Aggarwal RR, von Amsberg G, Joerger M, Imbimbo M, Colombo I, Gillessen S, Pedrani M. DLL3-Targeted Strategies in Advanced Prostate Cancer: Current Evidence and Future Perspectives. Drugs. 2026. PMID: 42527846

Borate UM, Huang Y, Lin TL, Handa S, Swords R, Lachowiez CA, Traer E, Stock W, Odenike O, Patel AA, Baer MR, Duong VH, Stein EM, Blum W, Vale CA, Curran E, Madanat YF, Olin RL, Schiller GJ, Nichols AD, Williams L, Heerema NA, Johnson MF, Chen TL, Marcus S, Martycz M, Stefanos M, Rosenberg L, DeGennaro LJ, Gruenbaum L, Burd A, Byrd JC, Druker BJ, Levine RL, Yocum AO, Mims AS, Zeidner JF. OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML. Blood. 2026. PMID: 42520193

Stefan DC, Dee EC, Ting FIL, Buckle GC. Rethinking cancer control in low- and middle-income countries: from workforce expansion to systems transformation. BMC cancer. 2026. PMID: 42509545

Wang B, Zou C, Zhang X, Fu L, Liu K, Song H, Wang G, Xie S, Zeng J, He S, Ai W, Wan L, Liu Y, Pan S, Li Y, Deng H, Yang F, Lu Y, Tang W, Fu X, Li J. Prevalence and correlates of depressive symptoms among young men who have sex with men: The role of family functioning and loneliness. Acta psychologica. 2026. PMID: 42520712

Lachowiez CA, Zeidner JF, Othman J, Kaempf A, Yun S, Heiblig M, Heuser M, Shahswar R, Marroquin RM, Cannova JM, Žucenka A, Marvin-Peek J, Senapati J, Abaza Y, Swaroop A, Zacheo I, Monaco F, Belhabri A, Tauveron-Jalenques U, Tavernier E, Carré M, Requena GA, Cook RJ, Traer E, Saultz JN, O'Nions J, Basheer F, Laurie J, Handa S, Stein EM, Baer MR, Olin R, Blum W, Schiller G, Lin T, Curran E, Yocum A, Madarang E, Daver N, Kadia TM, Marconi G, Madanat Y, Dillon R, DiNardo CD, Swords R, Arango Ossa JE, Watts J, Loghavi S, Pollyea DA, Bernard E, PRISM-AML Investigators. Erratum: Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 42507967

Lyubchenko T, Berdyshev E, Weight RM, Xiao O, Shah NJ, Markova A, Lacouture ME, Kern JA, Goleva E, Leung DYM. Skin Abnormalities at Checkpoint Inhibitor Therapy Initiation Are Associated With Skin Rash Development in Oncology Patients. Allergy. 2026. PMID: 42500847

Rugo HS. Response to correspondence received on "New perspectives on endocrine therapy suitability for hormone receptor-positive metastatic breast cancer in clinical practice". Breast (Edinburgh, Scotland). 2026. PMID: 42509147

Williams CL, Yang A, Gilmore S, Stanfield D, Steiding P, Atreya CE, Piawah S. "Doing My Part in My Healing": A Qualitative Study Exploring Integrative Oncology Practices Among African Americans with Cancer. Global advances in integrative medicine and health. 2026. PMID: 42495180

Krasnow NA, Salans M, Jayaraj M, Kuwahara K, Zhou MH, Boreta L, Braunstein SE, Aghi MK, Chien J, Rugo H, Melisko ME, Morshed RA, Vasudevan HN, Huppert LA. Clinical and molecular features of resected breast cancer brain metastases: a single center retrospective cohort study. Breast cancer research and treatment. 2026. PMID: 42474755

Trivedi A, Miyazawa B, Fields AT, Matthews M, Vivona L, Keane C, Potter D, Geng H, Zhang H, Taenaka H, Kwek SS, Herrera-Rodriguez K, Nunez-Garcia B, de Menezes EM, Barry M, Nair A, Kuhn B, Norris PJ, Fong L, Fitzpatrick MM, Schreiber M, Kornblith LZ, Pati S. Lyophilized platelet derived extracellular vesicles promote hemostasis and attenuate intracranial hemorrhage following traumatic brain injury. Journal of translational medicine. 2026. PMID: 42472813

Balas J, Bowling L, Shakhnazaryan N, Aggarwal RR, Borno HT, Hong JC, Huang FW, Tong B, Kwon DH. Evaluation of an Artificial Intelligence Communication Platform for Racial Biases in Pretest Education About Prostate Cancer Germline Testing. JCO clinical cancer informatics. 2026. PMID: 42475635

Grinda T, Heiling HM, Tayob N, Smith KL, Davis R, Cotter C, DeMeo MK, Santa-Maria CA, Van Poznak C, Moy B, Brufsky AM, Melisko ME, O'Sullivan CC, Isaacs C, Rauf Y, Nangia JR, Burns RT, Savoie J, Wolff AC, Winer EP, Mayer EL, Tolaney SM, Rimawi MF, Ruddy KJ, Rocque G, Krop IE, Lin NU, Freedman RA. Patient-reported outcomes from the TBCRC 022 study of neratinib and ado-trastuzumab emtansine for HER2-positive breast cancer brain metastases. Breast (Edinburgh, Scotland). 2026. PMID: 42501479

Thati N, Trudeau J, Ng DQ, Chavez-Iglesias E, Dhruva A, Olshen A, Chan R, Chan A, Kober KM. Perturbed Inflammatory, Proliferation, Regulatory, And Neurodegeneration Signaling Pathways Are Associated With Trait Anxiety In Cancer Survivors. Research square. 2026. PMID: 42523461